Timothy I. Mitchell

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.